• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Aharon Gil exercised 400,000 in-the-money shares at a strike of $10.00 (SEC Form 4)

    5/9/25 1:00:03 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care
    Get the next $DCTH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Aharon Gil

    (Last) (First) (Middle)
    15 WELLESLEY STREET WEST
    SUITE 326

    (Street)
    TORONTO A6 M4Y 0G7

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    DELCATH SYSTEMS, INC. [ DCTH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/05/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common shares 05/05/2025 X 400,000(1) A $10 3,413,468(2) I By Rosalind Advisors Inc., the advisor to the Rosalind Funds(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Rosalind Opportunities Fund I L.P. exercised warrants to aquire 400,000 common shares.
    2. Rosalind Master Fund L.P. - 1,565,844, Rosalind Opportunities Fund I L.P. - 1,734,545, Steven Salamon - 82,197, Gilad Aharon - 30,882
    3. Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein
    Aharon Gil 05/09/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DCTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DCTH

    DatePrice TargetRatingAnalyst
    6/28/2024$18.00Buy
    Craig Hallum
    5/14/2024$25.00Overweight
    Stephens
    7/26/2022$17.00Buy
    Canaccord Genuity
    12/10/2021$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $DCTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to eleven individuals whose employment commenced in March and April of 2025. The grants resulted in the right to purchase 111,000 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan ("Plan"). The options were granted on April 30, 2025, the date the Compensation Committee approved the stock option included within the equi

      5/9/25 5:30:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Reports First Quarter 2025 Results and Business Highlights

      Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024 HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in the first quarter of 2024 CHEMOSAT® revenue of $1.8 million, compared to $1.1 million in the first quarter of 2024 Gross margins of 86%, compared to 71% in the first quarter of 2

      5/8/25 7:30:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

      Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the Company's Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating HEPZATO™ in combination with standard of care (SOC) for liver-dominant metastatic breast cancer (mBC). With the FDA's review complete, Delcath is now cleared to initiate patient enrollment in the U.S. The Phase 2 trial will evaluate the safety and efficacy of HEPZATO in combination with SOC versus SOC alone in patients with liver-dominant HER2-negative mBC foll

      4/28/25 8:30:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

      10/2/24 4:43:10 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

      5/23/24 10:32:08 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-4) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 01/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

      1/23/24 4:36:46 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Delcath with a new price target

      Craig Hallum initiated coverage of Delcath with a rating of Buy and set a new price target of $18.00

      6/28/24 8:18:39 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Stephens initiated coverage on Delcath with a new price target

      Stephens initiated coverage of Delcath with a rating of Overweight and set a new price target of $25.00

      5/14/24 7:58:22 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Canaccord Genuity resumed coverage on Delcath with a new price target

      Canaccord Genuity resumed coverage of Delcath with a rating of Buy and set a new price target of $17.00

      7/26/22 9:10:21 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

      SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/15/24 10:33:51 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

      SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/14/24 9:46:56 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Delcath Systems Inc.

      SC 13G/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/14/24 7:02:01 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Financials

    Live finance-specific insights

    See more
    • Delcath Systems Reports First Quarter 2025 Results and Business Highlights

      Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024 HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in the first quarter of 2024 CHEMOSAT® revenue of $1.8 million, compared to $1.1 million in the first quarter of 2024 Gross margins of 86%, compared to 71% in the first quarter of 2

      5/8/25 7:30:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems to Host First Quarter 2025 Earnings Call

      Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 8, 2025, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, May 8, 2025 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1713022&tp_key=6de250d858 A replay of the webinar will be available shortly a

      4/24/25 4:01:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

      Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2024. Fourth Quarter and Full Year 2024 Financial Results Total fourth quarter and full year revenue of $15.1 million and $37.2 million, respectively HEPZATO KIT™ fourth quarter and full year revenue of $13.7 million and $32.3 million, respectively CHEMOSAT® fourth quarter and full year revenue of $1.4 million and $4.9 million, respectively Gross mar

      3/6/25 8:00:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    SEC Filings

    See more
    • SEC Form 10-Q filed by Delcath Systems Inc.

      10-Q - DELCATH SYSTEMS, INC. (0000872912) (Filer)

      5/8/25 9:25:44 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)

      5/8/25 7:42:05 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Delcath Systems Inc.

      DEFA14A - DELCATH SYSTEMS, INC. (0000872912) (Filer)

      4/1/25 8:58:05 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Beta Bionics Announces Board Appointment of Gerard Michel

      IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

      3/27/25 4:45:06 PM ET
      $BBNX
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa

      5/28/24 9:30:00 AM ET
      $ACHV
      $ALGS
      $DCTH
      $PNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medical/Dental Instruments
    • Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

      NEW YORK, March 18, 2024 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Martha S. Rook as its new Chief Operating Officer (COO). Martha S. Rook, Ph.D., is an experienced industry leader who brings more than 25 years of academic and industry experience in molecular biology, diagnostics development, biologics process development and biologics manufacturing. She joins Delcath from insitro where she

      3/18/24 5:20:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Aharon Gil exercised 400,000 in-the-money shares at a strike of $10.00 (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      5/9/25 1:00:03 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Director Salamon Steven A J exercised 400,000 in-the-money shares at a strike of $10.00 (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      5/9/25 12:36:53 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Director Rosalind Advisors, Inc. exercised 400,000 in-the-money shares at a strike of $10.00 (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      5/9/25 12:15:14 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Aharon Gil bought $100,001 worth of shares (26,882 units at $3.72), increasing direct ownership by 3% to 1,069,710 units (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      3/20/24 8:00:14 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Salamon Steven A J bought $100,001 worth of shares (26,882 units at $3.72), increasing direct ownership by 2% to 1,121,025 units (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      3/20/24 7:44:56 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Vukovic Vojo bought $120,000 worth of shares (40,000 units at $3.00), increasing direct ownership by 67% to 100,000 units (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      12/14/23 4:20:16 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care